MX357841B - Antagonistas de los receptores de la hormona liberadora de gonadotropina, método para la preparación de éstos y composición farmacéutica que los contienen. - Google Patents
Antagonistas de los receptores de la hormona liberadora de gonadotropina, método para la preparación de éstos y composición farmacéutica que los contienen.Info
- Publication number
- MX357841B MX357841B MX2014010345A MX2014010345A MX357841B MX 357841 B MX357841 B MX 357841B MX 2014010345 A MX2014010345 A MX 2014010345A MX 2014010345 A MX2014010345 A MX 2014010345A MX 357841 B MX357841 B MX 357841B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- receptor antagonists
- same
- hormone receptor
- releasing hormone
- Prior art date
Links
- 229940127445 Gonadotropin Releasing Hormone Receptor Antagonists Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 2
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 1
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000000736 Amenorrhea Diseases 0.000 abstract 1
- 206010001928 Amenorrhoea Diseases 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 102000006771 Gonadotropins Human genes 0.000 abstract 1
- 108010086677 Gonadotropins Proteins 0.000 abstract 1
- 206010020864 Hypertrichosis Diseases 0.000 abstract 1
- 208000037093 Menstruation Disturbances Diseases 0.000 abstract 1
- 206010027339 Menstruation irregular Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 abstract 1
- 201000005746 Pituitary adenoma Diseases 0.000 abstract 1
- 206010061538 Pituitary tumour benign Diseases 0.000 abstract 1
- 206010036618 Premenstrual syndrome Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 208000020221 Short stature Diseases 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 231100000360 alopecia Toxicity 0.000 abstract 1
- 231100000540 amenorrhea Toxicity 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002710 gonadal effect Effects 0.000 abstract 1
- 239000003163 gonadal steroid hormone Substances 0.000 abstract 1
- 239000002622 gonadotropin Substances 0.000 abstract 1
- 208000000509 infertility Diseases 0.000 abstract 1
- 230000036512 infertility Effects 0.000 abstract 1
- 231100000535 infertility Toxicity 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 208000021310 pituitary gland adenoma Diseases 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
- 208000006155 precocious puberty Diseases 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120020479 | 2012-02-28 | ||
| PCT/KR2013/001660 WO2013129879A1 (en) | 2012-02-28 | 2013-02-28 | Gonadotropin releasing hormone receptor antagonists, method for the preparation thereof and pharmaceutical composition comprising the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014010345A MX2014010345A (es) | 2014-11-14 |
| MX357841B true MX357841B (es) | 2018-07-26 |
Family
ID=49082998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014010345A MX357841B (es) | 2012-02-28 | 2013-02-28 | Antagonistas de los receptores de la hormona liberadora de gonadotropina, método para la preparación de éstos y composición farmacéutica que los contienen. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9481684B2 (https=) |
| EP (1) | EP2820021B1 (https=) |
| JP (1) | JP6209171B2 (https=) |
| KR (1) | KR101495260B1 (https=) |
| CN (2) | CN105732649B (https=) |
| AU (1) | AU2013226661B2 (https=) |
| BR (1) | BR112014021331B1 (https=) |
| CA (1) | CA2865547C (https=) |
| ES (1) | ES2613856T3 (https=) |
| MX (1) | MX357841B (https=) |
| WO (1) | WO2013129879A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10005781B2 (en) | 2013-10-30 | 2018-06-26 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Pyrazolopyrimidone or pyrrolotriazone derivatives, method of preparing same, and pharmaceutical applications thereof |
| JP2020528060A (ja) * | 2017-07-28 | 2020-09-17 | 江蘇恒瑞医薬股▲ふん▼有限公司 | ピリミドンヘテロアリール誘導体の製造方法およびピリミドンヘテロアリール誘導体の中間体 |
| KR101973074B1 (ko) * | 2018-11-30 | 2019-04-26 | 주식회사 티움바이오 | 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물 |
| CN109651265A (zh) * | 2019-02-16 | 2019-04-19 | 安徽诺全药业有限公司 | 一种Elagolix的制备方法 |
| ES2944511T3 (es) | 2019-03-26 | 2023-06-21 | Novel Pharma Inc | Derivado de GnRH que se une a ácido graso de acción prolongada y composición farmacéutica que comprende el mismo |
| KR20210155350A (ko) | 2020-06-15 | 2021-12-22 | 한상왕 | 녹차 추출물 및 비타민 d3를 유효성분으로 포함하는 자궁근종 개선용 조성물 |
| CN115124545B (zh) * | 2022-08-31 | 2023-01-03 | 南京远淑医药科技有限公司 | 一种促性腺激素释放激素受体拮抗剂中间体的合成方法 |
| KR102738115B1 (ko) | 2024-03-25 | 2024-12-05 | 한상왕 | 자궁근종 예방, 개선 또는 치료용 약학 조성물 |
| WO2025230335A1 (ko) * | 2024-05-03 | 2025-11-06 | 주식회사 티움바이오 | 에스트로겐-의존성 질환 치료 또는 예방용 약학적 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2163325A1 (en) * | 1994-11-21 | 1996-05-22 | Kaneyoshi Kato | Amine compounds, their production and use |
| US6156772A (en) | 1997-06-05 | 2000-12-05 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| TWI225863B (en) * | 1999-03-24 | 2005-01-01 | Takeda Chemical Industries Ltd | Thienopyrimidine compounds, their production and use |
| DE60022769T2 (de) * | 1999-10-15 | 2006-07-06 | Neurocrine Biosciences, Inc., San Diego | Gonadotropin freisetzenden hormon rezeptor antagonisten und ihre verwandten verwendungen |
| JP2005500356A (ja) * | 2001-08-02 | 2005-01-06 | ニューロクライン バイオサイエンシーズ， インコーポレイテッド | ゴナドトロピン放出ホルモンレセプターアンタゴニスト |
| FR2833948B1 (fr) * | 2001-12-21 | 2004-02-06 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et leur utilisation en tant que medicament |
| BR0312123A (pt) | 2002-06-13 | 2005-03-29 | Pfizer | Agentes de gnrh não peptìdicos, composições farmacêuticas e métodos para o seu uso |
| ES2494842T3 (es) * | 2005-07-22 | 2014-09-16 | Takeda Pharmaceutical Company Limited | Agente que previene la ovulación precoz |
| US9034850B2 (en) * | 2009-11-20 | 2015-05-19 | Sk Chemicals Co., Ltd. | Gonadotropin releasing hormone receptor antagonist, preparation method thereof and pharmaceutical composition comprising the same |
-
2013
- 2013-02-28 CN CN201610104516.XA patent/CN105732649B/zh active Active
- 2013-02-28 WO PCT/KR2013/001660 patent/WO2013129879A1/en not_active Ceased
- 2013-02-28 KR KR20130022105A patent/KR101495260B1/ko active Active
- 2013-02-28 BR BR112014021331-3A patent/BR112014021331B1/pt active IP Right Grant
- 2013-02-28 CN CN201380011513.6A patent/CN104136441B/zh active Active
- 2013-02-28 JP JP2014559833A patent/JP6209171B2/ja active Active
- 2013-02-28 EP EP13754960.6A patent/EP2820021B1/en active Active
- 2013-02-28 CA CA2865547A patent/CA2865547C/en active Active
- 2013-02-28 ES ES13754960T patent/ES2613856T3/es active Active
- 2013-02-28 MX MX2014010345A patent/MX357841B/es active IP Right Grant
- 2013-02-28 AU AU2013226661A patent/AU2013226661B2/en active Active
- 2013-02-28 US US14/381,371 patent/US9481684B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2865547A1 (en) | 2013-09-06 |
| CN105732649A (zh) | 2016-07-06 |
| EP2820021B1 (en) | 2016-11-30 |
| US20150166558A1 (en) | 2015-06-18 |
| AU2013226661A1 (en) | 2014-10-16 |
| CN105732649B (zh) | 2019-02-05 |
| EP2820021A4 (en) | 2015-10-21 |
| MX2014010345A (es) | 2014-11-14 |
| CN104136441A (zh) | 2014-11-05 |
| AU2013226661B2 (en) | 2017-08-31 |
| JP6209171B2 (ja) | 2017-10-04 |
| US9481684B2 (en) | 2016-11-01 |
| KR20130102002A (ko) | 2013-09-16 |
| BR112014021331A8 (pt) | 2017-10-10 |
| EP2820021A1 (en) | 2015-01-07 |
| BR112014021331B1 (pt) | 2020-12-15 |
| ES2613856T3 (es) | 2017-05-26 |
| WO2013129879A1 (en) | 2013-09-06 |
| CN104136441B (zh) | 2016-09-28 |
| CA2865547C (en) | 2020-03-10 |
| KR101495260B1 (ko) | 2015-02-26 |
| BR112014021331A2 (https=) | 2017-06-20 |
| JP2015510868A (ja) | 2015-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX357841B (es) | Antagonistas de los receptores de la hormona liberadora de gonadotropina, método para la preparación de éstos y composición farmacéutica que los contienen. | |
| MX2010008816A (es) | Metodo para tratar el cancer de prostata con el antagonista de gnrh degarelix. | |
| WO2015013389A3 (en) | Anti-galectin-1 (gal1) monoclonal antibodies and fragments thereof for neutralizing gal1 | |
| NZ589776A (en) | Performing handoff to a femto-enabled device when communication devices are in close proximity to the femto-enabled device | |
| WO2006009734A8 (en) | Gonadotropin releasing hormone receptor antagonists | |
| EP2680204A3 (en) | Mobile terminal and controlling method thereof | |
| MX2010012846A (es) | Dispositivos y metodos para iniciar funciones con base en caracteristicas de movimiento con relacion a una referencia. | |
| EP2373092A3 (en) | A wireless LAN terminal, a wireless LAN access point and a wireless LAN system | |
| BR112013031001A2 (pt) | método, programa de computador e aparelho | |
| MY172783A (en) | Application popularization method, device and system | |
| WO2006058012A3 (en) | Gonadotropin releasing hormone receptor antagonists | |
| WO2009134725A3 (en) | Monomethylamine progesteron antagonists such as cdb-4453 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc | |
| WO2011127388A3 (en) | Inverse agonists and neutral antagonists for the tsh receptor | |
| Shen et al. | Molecular phylogeny and divergence time estimates using the mitochondrial genome for the hadal snailfish from the Mariana trench | |
| MX2009009514A (es) | Heterociclos sulfonilados utiles para la modulacion del receptor de progesterona. | |
| PH12015502318A1 (en) | Spiroindoline derivatives for use as gonadotropin-releasing hormone receptor antagonists | |
| PH12016500044A1 (en) | Vasopressin-2 receptor agonists | |
| CN116096371A8 (zh) | 含有饱和含氧杂环基的嘧啶二酮类化合物及其用途 | |
| Oefelein | Re: Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry: TM van der Sluis, HN Bui, EJ Meuleman, AC Heijboer, JF Hartman, N. van Adrichem, E. Boevé, W. de Ronde, RJ van Moorselaar and AN Vis. J Urol 2012; 187: 1601-1606 | |
| FR2962850B1 (fr) | Dispositif et procede pour former sur un nanofil en semi-conducteur un alliage de ce semi-conducteur avec un metal ou un metalloide. | |
| Ree et al. | Energy Flow and Bond Dissociation of Vibrationally Excited Toluene in Collisions with N 2 and O 2 | |
| Jinling | Sidelights of CAFIU Delegation's Visit to Japan and Thailand | |
| TH142786A (th) | ของผสมบิทูเมนที่ดำเนินกรรมวิธีสำหรับเทถนนที่อุณหภูมิลดลง | |
| FENG et al. | Determination of potential carcinogenic and genotoxic sulfonate impurities in imatinib mesylate by a highly sensitive liquid chromatography-mass spectrometry method | |
| Zhang et al. | Retraction of “Phase Equilibrium for the Ternary System NaH2PO4+ KH2PO4+ H2O at 288.15 and 318.15 K” |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: TIUMBIO CO., LTD. |
|
| FG | Grant or registration |